Abbott Laboratories (Pakistan) Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PK0025701019
PKR
994.67
55.02 (5.86%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Company has very low debt and has enough cash to service the debt requirements

 
2

The company has declared Positive results for the last 6 consecutive quarters

3

With ROE of 21.8, it has a attractive valuation with a 3.8 Price to Book Value

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

PKR 81,935 Million (Large Cap)

stock-summary
P/E

18.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

1.19%

stock-summary
Debt Equity

-0.31

stock-summary
Return on Equity

23.46%

stock-summary
Price to Book

2.89

Revenue and Profits:
Net Sales:
19,819 Million
(Quarterly Results - Sep 2025)
Net Profit:
1,823 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-5.96%
0%
-5.96%
6 Months
-11.4%
0%
-11.4%
1 Year
44.14%
0%
44.14%
2 Years
153.13%
0%
153.13%
3 Years
48.52%
0%
48.52%
4 Years
27.69%
0%
27.69%
5 Years
69.59%
0%
69.59%

Abbott Laboratories (Pakistan) Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
17.90%
EBIT Growth (5y)
16.47%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.27
Sales to Capital Employed (avg)
2.91
Tax Ratio
45.92%
Dividend Payout Ratio
18.70%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
73.44%
ROE (avg)
21.43%

Valuation key factors

Factor
Value
P/E Ratio
18
Industry P/E
Price to Book Value
4.43
EV to EBIT
9.71
EV to EBITDA
8.35
EV to Capital Employed
5.69
EV to Sales
1.52
PEG Ratio
0.16
Dividend Yield
0.84%
ROCE (Latest)
58.62%
ROE (Latest)
25.11%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 3.98% vs 9.89% in Jun 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is -6.23% vs 21.49% in Jun 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "19,819.10",
          "val2": "19,061.30",
          "chgp": "3.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3,723.30",
          "val2": "3,704.00",
          "chgp": "0.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "17.70",
          "val2": "33.80",
          "chgp": "-47.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,822.50",
          "val2": "1,943.50",
          "chgp": "-6.23%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "145.50%",
          "val2": "168.50%",
          "chgp": "-2.30%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 22.90% vs 12.62% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 1,899.31% vs -91.29% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "68,177.20",
          "val2": "55,475.30",
          "chgp": "22.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "10,134.30",
          "val2": "3,528.90",
          "chgp": "187.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "23.60",
          "val2": "30.30",
          "chgp": "-22.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "500.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "5,234.20",
          "val2": "261.80",
          "chgp": "1,899.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "122.50%",
          "val2": "35.10%",
          "chgp": "8.74%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQstock-summary

Sep'25
Jun'25
Change(%)
Net Sales
19,819.10
19,061.30
3.98%
Operating Profit (PBDIT) excl Other Income
3,723.30
3,704.00
0.52%
Interest
17.70
33.80
-47.63%
Exceptional Items
0.00
0.00
Consolidate Net Profit
1,822.50
1,943.50
-6.23%
Operating Profit Margin (Excl OI)
145.50%
168.50%
-2.30%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2025 is 3.98% vs 9.89% in Jun 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is -6.23% vs 21.49% in Jun 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
68,177.20
55,475.30
22.90%
Operating Profit (PBDIT) excl Other Income
10,134.30
3,528.90
187.18%
Interest
23.60
30.30
-22.11%
Exceptional Items
0.00
500.10
-100.00%
Consolidate Net Profit
5,234.20
261.80
1,899.31%
Operating Profit Margin (Excl OI)
122.50%
35.10%
8.74%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 22.90% vs 12.62% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 1,899.31% vs -91.29% in Dec 2023

stock-summaryCompany CV
About Abbott Laboratories (Pakistan) Ltd. stock-summary
stock-summary
Abbott Laboratories (Pakistan) Ltd.
Pharmaceuticals & Biotechnology
Abbott Laboratories (Pakistan) Limited is a Pakistan-based healthcare company. The Company is engaged in the manufacture, import and marketing of research-based pharmaceutical, nutritional, diagnostic, diabetic care, hospital and consumer products. The Company's segments include Pharmaceutical, Nutritional and Others. The Pharmaceutical segment is engaged in the manufacture, import and marketing of research-based pharmaceutical products registered with the Drug Regulatory Authority of Pakistan. The Nutritional segment is engaged in the import and marketing of pediatric nutritional products and medical nutritional products. The Others segment represents the manufacture, import and marketing of diagnostic equipment, diabetes care, molecular devices, their testing kits and general healthcare products. The Company has its presence in various therapeutic areas, including gastroenterology, pain, respiratory, cardio vascular and metabolic, and women's and men's health, among others.
Company Coordinates stock-summary
Company Details
Opposite Radio Pakistan Transmission Hyderabad Road, Landhi. KARACHI None : 75120
stock-summary
Tel: 92 21 35069748
stock-summary
Registrar Details